{"gene":"KLKB1","run_date":"2026-06-10T02:59:49","timeline":{"discoveries":[{"year":2014,"finding":"Klkb1-/- mice have reduced thrombosis via a pathway involving increased Mas receptor, prostacyclin, Sirt1, and KLF4, and decreased tissue factor (TF). Pharmacological blockade of Mas receptor (A-779), COX-2 (nimesulide), or Sirt1 (splitomicin) in Klkb1-/- mice lowered plasma prostacyclin and normalized arterial thrombosis times, establishing a mechanistic chain: loss of KLKB1 → reduced bradykinin delivery → increased Mas/prostacyclin/Sirt1/KLF4 → reduced vascular TF.","method":"Genetic knockout mouse model (Klkb1-/-), pharmacological inhibition (Mas antagonist, COX-2 inhibitor, Sirt1 inhibitor), thrombosis models (rose bengal, ferric chloride, collagen/epinephrine, polyphosphate), plasma prostacyclin measurement, aortic TF mRNA/antigen/activity assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vivo rescue experiments (pharmacological inhibitors normalizing phenotype) combined with mechanistic pathway dissection across multiple readouts in a single rigorous study","pmids":["25339356"],"is_preprint":false},{"year":2016,"finding":"Plasma kallikrein (encoded by KLKB1) directly cleaves human recombinant pro-renin to generate active renin in vitro, which then digests angiotensinogen to angiotensin-I, placing KLKB1 in the renin-angiotensin activation cascade. Co-localization of kallikrein with renin was confirmed in mouse juxtaglomerular cells and kidney sections.","method":"In vitro enzymatic digestion assay (recombinant pro-renin + kallikrein), immunofluorescence co-localization in mouse juxtaglomerular cell line and kidney sections, genetic association with plasma renin levels","journal":"BMC medical genetics","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro reconstitution of pro-renin cleavage by kallikrein with functional downstream readout (angiotensin-I generation), supported by cellular co-localization, single lab","pmids":["26969407"],"is_preprint":false},{"year":2025,"finding":"KLKB1 interacts with transcription factor TFE3 (identified by IP-MS and confirmed by Co-IP), and this interaction promotes ferroptosis in vascular dementia neurons via the BRaf/MEK/ERK signaling cascade. Knockdown of KLKB1 decreased TFE3 expression and suppressed ferroptosis through inhibition of BRaf/MEK/ERK; TFE3 knockdown produced the same antiferroptotic effect.","method":"Immunoprecipitation-mass spectrometry (IP-MS), co-immunoprecipitation (Co-IP), immunofluorescence, siRNA knockdown of KLKB1 and TFE3, Western blotting, qPCR, rat BCCAO model of vascular dementia, transcriptome sequencing","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal protein interaction validated by IP-MS and Co-IP, genetic knockdown with pathway-level phenotype rescue, single lab","pmids":["41242565"],"is_preprint":false},{"year":2024,"finding":"In vivo CRISPR-Cas9 editing of KLKB1 (via NTLA-2002) in humans produced dose-dependent reductions in total plasma kallikrein protein levels (up to -95% at 75 mg), demonstrating that KLKB1 gene disruption directly controls plasma kallikrein levels and thereby reduces hereditary angioedema attacks.","method":"Phase 1 clinical trial, in vivo CRISPR-Cas9 gene editing (lipid nanoparticle delivery), plasma kallikrein protein quantification, clinical attack-rate monitoring","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — prospective dose-escalation human trial with pharmacodynamic protein-level readout replicated across multiple dose cohorts, establishing direct causal link between KLKB1 expression and plasma kallikrein level","pmids":["38294975"],"is_preprint":false}],"current_model":"KLKB1 encodes plasma prekallikrein, a serine protease that, when activated to plasma kallikrein, cleaves kininogens to release bradykinin, cleaves pro-renin to generate active renin (thereby feeding into the renin-angiotensin system), and interacts with TFE3 to drive BRaf/MEK/ERK-mediated ferroptosis; loss of KLKB1 function reduces vascular tissue factor and thrombosis via a compensatory Mas receptor/prostacyclin/Sirt1/KLF4 axis, and in vivo CRISPR-based ablation of KLKB1 in humans dose-dependently eliminates plasma kallikrein protein and prevents hereditary angioedema attacks."},"narrative":{"mechanistic_narrative":"KLKB1 encodes plasma prekallikrein, the zymogen of plasma kallikrein, a serine protease that operates at the interface of the kinin, renin-angiotensin, and coagulation systems [PMID:26969407, PMID:38294975]. In vivo CRISPR-Cas9 disruption of KLKB1 in humans produces dose-dependent loss of plasma kallikrein protein and prevents hereditary angioedema attacks, establishing that KLKB1 expression directly sets circulating kallikrein levels [PMID:38294975]. Catalytically, plasma kallikrein cleaves pro-renin to generate active renin, which in turn liberates angiotensin-I from angiotensinogen, placing KLKB1 upstream of the renin-angiotensin activation cascade, with kallikrein co-localizing with renin in juxtaglomerular cells [PMID:26969407]. Loss of KLKB1 reduces arterial thrombosis through a defined signaling chain in which diminished bradykinin delivery elevates Mas receptor, prostacyclin, Sirt1, and KLF4 signaling and lowers vascular tissue factor [PMID:25339356]. Beyond these roles, KLKB1 physically interacts with the transcription factor TFE3 to promote BRaf/MEK/ERK-driven ferroptosis in vascular dementia neurons [PMID:41242565].","teleology":[{"year":2014,"claim":"Established that KLKB1 loss is not merely a deficiency in clotting initiation but actively reprograms vascular signaling, answering how prekallikrein modulates thrombosis risk through downstream effector axes.","evidence":"Klkb1-/- mice with pharmacological rescue using Mas, COX-2, and Sirt1 inhibitors across multiple thrombosis models, with prostacyclin and aortic tissue factor readouts","pmids":["25339356"],"confidence":"High","gaps":["Does not establish whether the Mas/prostacyclin/Sirt1/KLF4 axis operates identically in humans","The direct molecular link between reduced bradykinin and Mas receptor upregulation is inferred, not biochemically resolved","Does not address the catalytic mechanism of prekallikrein activation in this context"]},{"year":2016,"claim":"Placed KLKB1 within the renin-angiotensin activation cascade by showing plasma kallikrein can directly convert pro-renin to active renin, answering whether kallikrein has a substrate beyond kininogen.","evidence":"In vitro enzymatic digestion of recombinant pro-renin by kallikrein with angiotensin-I generation readout, plus immunofluorescence co-localization in juxtaglomerular cells and kidney sections","pmids":["26969407"],"confidence":"Medium","gaps":["Single-lab in vitro reconstitution; physiological contribution to renin activation in vivo not quantified","Co-localization does not demonstrate functional pro-renin processing in intact tissue","Cleavage site and kinetic parameters not defined"]},{"year":2024,"claim":"Demonstrated a direct causal link between KLKB1 gene dosage and circulating kallikrein protein in humans, answering whether KLKB1 disruption is therapeutically sufficient to control kallikrein-driven disease.","evidence":"Phase 1 dose-escalation trial of in vivo CRISPR-Cas9 editing (NTLA-2002, lipid nanoparticle delivery) with plasma kallikrein quantification and angioedema attack-rate monitoring","pmids":["38294975"],"confidence":"High","gaps":["Long-term durability of editing and off-target effects not addressed in this early-phase report","Does not characterize compensatory consequences of chronic kallikrein loss in humans"]},{"year":2025,"claim":"Identified a non-canonical role for KLKB1 as a partner of transcription factor TFE3 driving neuronal ferroptosis, answering whether KLKB1 acts beyond plasma proteolysis.","evidence":"IP-MS and reciprocal Co-IP identifying TFE3 interaction, siRNA knockdown of KLKB1 and TFE3, and BRaf/MEK/ERK pathway readouts in a rat BCCAO vascular dementia model","pmids":["41242565"],"confidence":"Medium","gaps":["Single-lab finding; the structural basis and cellular compartment of a protease-transcription factor interaction are undefined","Whether kallikrein catalytic activity is required for the TFE3/ferroptosis effect is unresolved","Mechanism by which KLKB1 knockdown lowers TFE3 expression is not established"]},{"year":null,"claim":"How a secreted plasma protease physically and functionally engages an intracellular transcription factor, and how its distinct kinin, renin, thrombosis, and ferroptosis roles are coordinated, remains unresolved.","evidence":"No timeline discovery reconciles the extracellular proteolytic functions with the intracellular TFE3/ferroptosis role","pmids":[],"confidence":"Low","gaps":["No structural model of the KLKB1-TFE3 complex","No reconciliation of secreted versus intracellular function","Relative physiological weighting of pro-renin versus kininogen substrates unquantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1]}],"localization":[],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[0]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2]}],"complexes":[],"partners":["TFE3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P03952","full_name":"Plasma kallikrein","aliases":["Fletcher factor","Kininogenin","Plasma prekallikrein","PKK"],"length_aa":638,"mass_kda":71.3,"function":"Participates in the surface-dependent activation of blood coagulation. Activates, in a reciprocal reaction, coagulation factor XII/F12 after binding to negatively charged surfaces. Releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P03952/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/KLKB1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/KLKB1","total_profiled":1310},"omim":[{"mim_id":"615144","title":"PROTEASE, SERINE, 55; PRSS55","url":"https://www.omim.org/entry/615144"},{"mim_id":"612423","title":"PREKALLIKREIN DEFICIENCY; PKKD","url":"https://www.omim.org/entry/612423"},{"mim_id":"600636","title":"CASPASE 3, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP3","url":"https://www.omim.org/entry/600636"},{"mim_id":"229000","title":"KALLIKREIN B, PLASMA, 1; KLKB1","url":"https://www.omim.org/entry/229000"},{"mim_id":"228960","title":"HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY","url":"https://www.omim.org/entry/228960"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":306.8}],"url":"https://www.proteinatlas.org/search/KLKB1"},"hgnc":{"alias_symbol":[],"prev_symbol":["KLK3"]},"alphafold":{"accession":"P03952","domains":[{"cath_id":"3.50.4.10","chopping":"26-108","consensus_level":"high","plddt":93.4858,"start":26,"end":108},{"cath_id":"3.50.4.10","chopping":"116-195","consensus_level":"high","plddt":95.449,"start":116,"end":195},{"cath_id":"3.50.4.10","chopping":"206-280","consensus_level":"medium","plddt":95.2908,"start":206,"end":280},{"cath_id":"3.50.4.10","chopping":"294-371","consensus_level":"medium","plddt":96.0522,"start":294,"end":371},{"cath_id":"2.40.10.10","chopping":"396-620","consensus_level":"medium","plddt":88.8388,"start":396,"end":620}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P03952","model_url":"https://alphafold.ebi.ac.uk/files/AF-P03952-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P03952-F1-predicted_aligned_error_v6.png","plddt_mean":87.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=KLKB1","jax_strain_url":"https://www.jax.org/strain/search?query=KLKB1"},"sequence":{"accession":"P03952","fasta_url":"https://rest.uniprot.org/uniprotkb/P03952.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P03952/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P03952"}},"corpus_meta":[{"pmid":"38294975","id":"PMC_38294975","title":"CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema.","date":"2024","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38294975","citation_count":133,"is_preprint":false},{"pmid":"25339356","id":"PMC_25339356","title":"Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25339356","citation_count":74,"is_preprint":false},{"pmid":"32202057","id":"PMC_32202057","title":"Severe plasma prekallikrein deficiency: Clinical characteristics, novel KLKB1 mutations, and estimated prevalence.","date":"2020","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/32202057","citation_count":26,"is_preprint":false},{"pmid":"25891023","id":"PMC_25891023","title":"KLKB1 mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia.","date":"2015","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25891023","citation_count":24,"is_preprint":false},{"pmid":"17318641","id":"PMC_17318641","title":"Common variation in KLKB1 and essential hypertension risk: tagging-SNP haplotype analysis in a case-control study.","date":"2007","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17318641","citation_count":19,"is_preprint":false},{"pmid":"26969407","id":"PMC_26969407","title":"Polymorphisms at the F12 and KLKB1 loci have significant trait association with activation of the renin-angiotensin system.","date":"2016","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26969407","citation_count":18,"is_preprint":false},{"pmid":"27200353","id":"PMC_27200353","title":"A Cross-sectional Study of KLKB1 and PRCP Polymorphisms in Patient Samples with Cardiovascular Disease.","date":"2016","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27200353","citation_count":15,"is_preprint":false},{"pmid":"19404525","id":"PMC_19404525","title":"[Severe prekallikrein deficiency due to a compound heterozygosis in the KLKB1-gene].","date":"2009","source":"Hamostaseologie","url":"https://pubmed.ncbi.nlm.nih.gov/19404525","citation_count":7,"is_preprint":false},{"pmid":"24066149","id":"PMC_24066149","title":"Regulation of the F11, Klkb1, Cyp4v3 gene cluster in livers of metabolically challenged mice.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24066149","citation_count":5,"is_preprint":false},{"pmid":"41242565","id":"PMC_41242565","title":"The KLKB1-TFE3-BRAF/MEK/ERK axis regulates neuronal ferroptosis in vascular dementia.","date":"2025","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/41242565","citation_count":1,"is_preprint":false},{"pmid":"26149136","id":"PMC_26149136","title":"Association between KLKB1 Polymorphisms and Pulmonary Thromboembolism.","date":"2015","source":"Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae","url":"https://pubmed.ncbi.nlm.nih.gov/26149136","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.01.30.635763","title":"Platform-dependent effects of genetic variants on plasma APOL1","date":"2025-02-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.30.635763","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":8778,"output_tokens":1438,"usd":0.023952,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8146,"output_tokens":2226,"usd":0.04819,"stage2_stop_reason":"end_turn"},"total_usd":0.072142,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"Klkb1-/- mice have reduced thrombosis via a pathway involving increased Mas receptor, prostacyclin, Sirt1, and KLF4, and decreased tissue factor (TF). Pharmacological blockade of Mas receptor (A-779), COX-2 (nimesulide), or Sirt1 (splitomicin) in Klkb1-/- mice lowered plasma prostacyclin and normalized arterial thrombosis times, establishing a mechanistic chain: loss of KLKB1 → reduced bradykinin delivery → increased Mas/prostacyclin/Sirt1/KLF4 → reduced vascular TF.\",\n      \"method\": \"Genetic knockout mouse model (Klkb1-/-), pharmacological inhibition (Mas antagonist, COX-2 inhibitor, Sirt1 inhibitor), thrombosis models (rose bengal, ferric chloride, collagen/epinephrine, polyphosphate), plasma prostacyclin measurement, aortic TF mRNA/antigen/activity assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vivo rescue experiments (pharmacological inhibitors normalizing phenotype) combined with mechanistic pathway dissection across multiple readouts in a single rigorous study\",\n      \"pmids\": [\"25339356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Plasma kallikrein (encoded by KLKB1) directly cleaves human recombinant pro-renin to generate active renin in vitro, which then digests angiotensinogen to angiotensin-I, placing KLKB1 in the renin-angiotensin activation cascade. Co-localization of kallikrein with renin was confirmed in mouse juxtaglomerular cells and kidney sections.\",\n      \"method\": \"In vitro enzymatic digestion assay (recombinant pro-renin + kallikrein), immunofluorescence co-localization in mouse juxtaglomerular cell line and kidney sections, genetic association with plasma renin levels\",\n      \"journal\": \"BMC medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro reconstitution of pro-renin cleavage by kallikrein with functional downstream readout (angiotensin-I generation), supported by cellular co-localization, single lab\",\n      \"pmids\": [\"26969407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"KLKB1 interacts with transcription factor TFE3 (identified by IP-MS and confirmed by Co-IP), and this interaction promotes ferroptosis in vascular dementia neurons via the BRaf/MEK/ERK signaling cascade. Knockdown of KLKB1 decreased TFE3 expression and suppressed ferroptosis through inhibition of BRaf/MEK/ERK; TFE3 knockdown produced the same antiferroptotic effect.\",\n      \"method\": \"Immunoprecipitation-mass spectrometry (IP-MS), co-immunoprecipitation (Co-IP), immunofluorescence, siRNA knockdown of KLKB1 and TFE3, Western blotting, qPCR, rat BCCAO model of vascular dementia, transcriptome sequencing\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal protein interaction validated by IP-MS and Co-IP, genetic knockdown with pathway-level phenotype rescue, single lab\",\n      \"pmids\": [\"41242565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In vivo CRISPR-Cas9 editing of KLKB1 (via NTLA-2002) in humans produced dose-dependent reductions in total plasma kallikrein protein levels (up to -95% at 75 mg), demonstrating that KLKB1 gene disruption directly controls plasma kallikrein levels and thereby reduces hereditary angioedema attacks.\",\n      \"method\": \"Phase 1 clinical trial, in vivo CRISPR-Cas9 gene editing (lipid nanoparticle delivery), plasma kallikrein protein quantification, clinical attack-rate monitoring\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — prospective dose-escalation human trial with pharmacodynamic protein-level readout replicated across multiple dose cohorts, establishing direct causal link between KLKB1 expression and plasma kallikrein level\",\n      \"pmids\": [\"38294975\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"KLKB1 encodes plasma prekallikrein, a serine protease that, when activated to plasma kallikrein, cleaves kininogens to release bradykinin, cleaves pro-renin to generate active renin (thereby feeding into the renin-angiotensin system), and interacts with TFE3 to drive BRaf/MEK/ERK-mediated ferroptosis; loss of KLKB1 function reduces vascular tissue factor and thrombosis via a compensatory Mas receptor/prostacyclin/Sirt1/KLF4 axis, and in vivo CRISPR-based ablation of KLKB1 in humans dose-dependently eliminates plasma kallikrein protein and prevents hereditary angioedema attacks.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"KLKB1 encodes plasma prekallikrein, the zymogen of plasma kallikrein, a serine protease that operates at the interface of the kinin, renin-angiotensin, and coagulation systems [#1, #3]. In vivo CRISPR-Cas9 disruption of KLKB1 in humans produces dose-dependent loss of plasma kallikrein protein and prevents hereditary angioedema attacks, establishing that KLKB1 expression directly sets circulating kallikrein levels [#3]. Catalytically, plasma kallikrein cleaves pro-renin to generate active renin, which in turn liberates angiotensin-I from angiotensinogen, placing KLKB1 upstream of the renin-angiotensin activation cascade, with kallikrein co-localizing with renin in juxtaglomerular cells [#1]. Loss of KLKB1 reduces arterial thrombosis through a defined signaling chain in which diminished bradykinin delivery elevates Mas receptor, prostacyclin, Sirt1, and KLF4 signaling and lowers vascular tissue factor [#0]. Beyond these roles, KLKB1 physically interacts with the transcription factor TFE3 to promote BRaf/MEK/ERK-driven ferroptosis in vascular dementia neurons [#2].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"Established that KLKB1 loss is not merely a deficiency in clotting initiation but actively reprograms vascular signaling, answering how prekallikrein modulates thrombosis risk through downstream effector axes.\",\n      \"evidence\": \"Klkb1-/- mice with pharmacological rescue using Mas, COX-2, and Sirt1 inhibitors across multiple thrombosis models, with prostacyclin and aortic tissue factor readouts\",\n      \"pmids\": [\"25339356\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Does not establish whether the Mas/prostacyclin/Sirt1/KLF4 axis operates identically in humans\",\n        \"The direct molecular link between reduced bradykinin and Mas receptor upregulation is inferred, not biochemically resolved\",\n        \"Does not address the catalytic mechanism of prekallikrein activation in this context\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Placed KLKB1 within the renin-angiotensin activation cascade by showing plasma kallikrein can directly convert pro-renin to active renin, answering whether kallikrein has a substrate beyond kininogen.\",\n      \"evidence\": \"In vitro enzymatic digestion of recombinant pro-renin by kallikrein with angiotensin-I generation readout, plus immunofluorescence co-localization in juxtaglomerular cells and kidney sections\",\n      \"pmids\": [\"26969407\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single-lab in vitro reconstitution; physiological contribution to renin activation in vivo not quantified\",\n        \"Co-localization does not demonstrate functional pro-renin processing in intact tissue\",\n        \"Cleavage site and kinetic parameters not defined\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated a direct causal link between KLKB1 gene dosage and circulating kallikrein protein in humans, answering whether KLKB1 disruption is therapeutically sufficient to control kallikrein-driven disease.\",\n      \"evidence\": \"Phase 1 dose-escalation trial of in vivo CRISPR-Cas9 editing (NTLA-2002, lipid nanoparticle delivery) with plasma kallikrein quantification and angioedema attack-rate monitoring\",\n      \"pmids\": [\"38294975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Long-term durability of editing and off-target effects not addressed in this early-phase report\",\n        \"Does not characterize compensatory consequences of chronic kallikrein loss in humans\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified a non-canonical role for KLKB1 as a partner of transcription factor TFE3 driving neuronal ferroptosis, answering whether KLKB1 acts beyond plasma proteolysis.\",\n      \"evidence\": \"IP-MS and reciprocal Co-IP identifying TFE3 interaction, siRNA knockdown of KLKB1 and TFE3, and BRaf/MEK/ERK pathway readouts in a rat BCCAO vascular dementia model\",\n      \"pmids\": [\"41242565\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single-lab finding; the structural basis and cellular compartment of a protease-transcription factor interaction are undefined\",\n        \"Whether kallikrein catalytic activity is required for the TFE3/ferroptosis effect is unresolved\",\n        \"Mechanism by which KLKB1 knockdown lowers TFE3 expression is not established\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a secreted plasma protease physically and functionally engages an intracellular transcription factor, and how its distinct kinin, renin, thrombosis, and ferroptosis roles are coordinated, remains unresolved.\",\n      \"evidence\": \"No timeline discovery reconciles the extracellular proteolytic functions with the intracellular TFE3/ferroptosis role\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural model of the KLKB1-TFE3 complex\",\n        \"No reconciliation of secreted versus intracellular function\",\n        \"Relative physiological weighting of pro-renin versus kininogen substrates unquantified\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TFE3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":4,"faith_total":5,"faith_pct":80.0}}